Valerio Therapeutics S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALVIO.PA research report →
About the company
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S. A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments.
- CEO
- Julien Miara
- IPO
- 2023
- Employees
- 38
- HQ
- Paris, FR
Price Chart
- Market Cap
- $69.65M
- P/E
- -6.28
- P/S
- 27.07
- P/B
- 14.82
- EV/EBITDA
- 140.60
- Div Yield
- 0.00%
- Gross Margin
- 67.08%
- Op Margin
- -21.38%
- Net Margin
- -190.36%
- ROE
- 139.11%
- ROIC
- -5.50%
- Revenue
- $2.57M · 43.50%
- Net Income
- $-4,898,000 · 79.53%
- EPS
- $-0.03 · 80.19%
- Op Income
- $-550,000
- FCF YoY
- 104.08%
- 52W High
- $0.31
- 52W Low
- $0.04
- 50D MA
- $0.18
- 200D MA
- $0.14
- Beta
- 1.81
- Avg Volume
- 289.66K
Get TickerSpark's AI analysis on ALVIO.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALVIO.PA coverage
Recent articles, reports, and earnings notes.
No research on ALVIO.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALVIO.PA report →Similar companies
Peers in the same neighborhood.